 | | | | Related Healthscout Videos | |
|
FRIDAY, March 19 (HealthDay News) -- People taking the highest approved doses of the cholesterol-lowering drug Zocor (simvastatin) may be at increased risk for muscle injuries, the U.S. Food and Drug Administration (FDA) warned Friday.
Although muscle pain and weakness, called myopathy, is a known side effect of all cholesterol-lowering drugs classified as statins, such as Zocor, the FDA said that people taking the 80 milligram dose face an especially high risk of developing muscle problems, including rhabdomyolysis, the most serious form of myopathy, which can lead to kidney damage, kidney failure and even death.
Text Continues Below
Reacting to the warning, Dr. Gregg Fonarow, a professor of cardiovascular medicine at the University of California, Los Angeles, said that patients shouldn't lose sight of the benefits of statin use.
"Statins, including simvastatin, have been shown to lower the risk of heart attack, strokes and premature cardiovascular deaths, and in most patients the benefits of statin treatment greatly outweigh the risks," he said.
While doses of simvastatin of 10 milligrams, 20 milligrams and 40 milligrams have side-effect profiles similar to other statin medications, the 80 milligram dose has been shown to have a higher risk of skeletal muscle injury, particularly in patients on other medications that may interact with simvastatin, Fonarow said.
"There are other statin medications which lower LDL -- bad cholesterol -- levels as well or better than the simvastatin 80 milligram dose and without the same degree of muscle injury risk," he said. "Patients should discuss with their physician which statin regimen and dosing is most appropriate for them."
The agency is advising patients taking the drug to talk with their doctors, before stopping or changing their medication.
"Review of simvastatin is part of an ongoing FDA effort to evaluate the risk of statin-associated muscle injury and to provide that information to the public as it becomes available, Dr. Eric Colman, deputy director of FDA's Division of Metabolism and Endocrinology Products, said in a statement. "It's important for patients and health care professionals to consider all the potential risks and known benefits of any drug before deciding on any one therapy or dose of therapy," he said.
Page: 1 | 2 | Next >>
|
.gif)
